Real-world safety and feasibility of ¹⁷⁷Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer: a retrospective tolerability analysis (EANM 2026) - Sep 29, 2026 - Abstract #EP-0938; "In this real-world cohort of heavily pre-treated mCRPC patients, ¹⁷⁷Lu-PSMA-617 showed a favourable tolerability profile, with infrequent Grade 3-4 haematological toxicity (5%), no Grade 4 events, no significant nephrotoxicity, and no toxicity-related discontinuations — consistent with pivotal trial data and supporting feasibility in routine practice."
Metastases • Real-world • Real-world evidence • Retrospective data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • Thrombocytopenia
|
|
S. Shamim; M. Umar; N. Damle; A. Batra
|